NCT06032858

Efficacy and Safety of Apremilast in Psoriasis

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Ghurki Trust and Teaching Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 59 Years
• Healthy volunteers: Not accepted

Summary

Psoriasis is a long standing inflammatory, autoinflammatory disease linked with many comorbidities. Patients with moderate to severe plaque psoriasis can be managed with topical as well as systemic medications. FDA approved Apremilast as first drug to be taken orally in cases of psoriasis in mid 1990's. Currently, according to researchers best knowledge no study has been done on use of Apremilast in Pakistan. It has recently become available here. Keeping in view all the benefits of this drug, a study has been planned to check its effectiveness and safety 30mg twice a day, in patients with moderate to severe chronic plaque psoriasis based on Psoriasis area and severity index and Body surface area assessments in our population.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Apremilast 30mg	Apremilast 30mg twice daily

Timeline

• Start date: 2022-03-06
• Primary completion: 2023-07-10
• Completion: 2023-08-10
• First posted: 2023-09-13
• Last updated: 2023-09-13

Locations

1 site across 1 country: Pakistan